3 completed, 2 not yet recruiting, 2 recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Monotherapy: new trials by email Literature Review of Monotherapy trials Research Report on Monotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial Actigraphy, Best Practice, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Theodore Brasky PhD | 50 | 2027-01-15 | 2026-10-14 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab(KEYTRUDA®), PMC-309 Dose Expansion - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | PharmAbcine | 67 | 2024-01-03 | 2025-12-30 |
| Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration PMC-403 - Neovascular Age-related Macular Degeneration | Phase 1 | Completed | PharmAbcine | 17 | 2023-07-20 | 2025-12-30 |
| HCW9218 in Select Advanced Solid Tumors HCW9218 - Solid Tumor | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 18 | 2022-04-01 | 2025-11-05 |
| A Trial of ZL-1201 in Subjects With Advanced Cancer ZL-1201 - Advanced Cancer | Phase 1 | Completed | Zai Lab (Shanghai) Co., Ltd. | 37 | 2020-05-11 | 2023-08-22 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) - Head and Neck Carcinoma, Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | VM Oncology, LLC | 242 | 2018-06-08 | 2025-12-11 |
Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Laryngeal Diseases (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tracheal Diseases (1)
PharmAbcine (2) · City of Hope Medical Center (1) · Masonic Cancer Center, University of Minnesota (1) · Theodore Brasky PhD (1) · VM Oncology, LLC (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (5) · Australia (1) · China (1) · Puerto Rico (1) · South Korea (1)
Andrea Tazbirkova, Dr (1) · Melissa Geller, MD (1) · Ryotaro Nakamura (1) · SeJoon Woo (1) · Theodore Brasky, PhD (1)
P30CA033572 (1)